Eltrombopag - Novartis

Drug Profile

Eltrombopag - Novartis

Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Novartis; Technische Universitat Dresden
  • Class Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 04 Jan 2018 Eltrombopag - Novartis receives Breakthrough Therapy status for Aplastic anaemia (First-line therapy) in USA
  • 04 Jan 2018 Novartis plans regulatory submissions for eltrombopag for Aplastic anaemia (First-line therapy) in USA and European Union in 2018
  • 06 Sep 2017 Novartis Pharmaceuticals completes a phase II trial in Aplastic anaemia (Combination therapy, Treatment-naive) in Japan (PO) (NCT02404025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top